U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07106749) titled 'CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies' on July 30.
Brief Summary: The objective of this study was to evaluate the safety and efficacy of CD180 CART cells in the treatment of patients with relapsed/refractory CD180-positive hematological malignancies. In this single-arm, open-label, single-center, Phase I clinical trial, two cohorts were set up: (1) relapsed and refractory AML cohort; and (2) relapsed and refractory B-ALL/LBL cohort. CD180 CART cells will be administered intravenously using a 3+3 dose escalation and rapid titration design, with CART dose groups of (1) 0.5x10^6 CART cells/kg;(2)1...